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Abstract
Background: Molecular imaging with nanoparticles makes non-invasive monitoring of target cells without sacrifice of subjects
and repeated evaluation possible.
Objectives: To evaluate the imaging feasibility of a rat animal model with erectile dysfunction (ED) by bilateral cavernosal nerve
injury using human mesenchymal stem cells (MSCs) labeled with superparamagnetic iron oxide (SPIO) and simultaneously to eval-
uate the beneficial effect of MSCs on ED.
Materials and Methods: Thirty-six rats were injected with MSCs labeled with SPIO particle into the corpus cavernosum after bilat-
eral cavernosal nerve injury. In vivo MR imaging was serially performed up to 16 weeks using 1.5 T clinical scanner. After MR imaging,
the penile specimens were evaluated for the expression of transforming growth factor-β1 (TGF-β1) by polymerase chain reaction.
Results: MR imaging showed a drop in signal intensity at the injection site in the stem cell-injected group. The size of hypointensity
was decreased in MSC-injected group in a time-dependent manner; whereas, signal void was not detected at the injection site in the
control group. In addition, polymeric chain reaction (PCR) analyses of penile tissues from both groups revealed that the mRNA
expression of TGF-β1 was significantly decreased in MSC-injected groups after 4 weeks of injection compared to the control group.
Conclusion: MSCs’ beneficial effects on ED was monitored with MR imaging, which might be a valuable tool for tracking and ther-
apeutic monitoring in the future clinical study of stem cell therapy in ED.
Keywords: Molecular Imaging, Nanoparticles, Stem Cells, Erectile Dysfunction, Transforming Growth Factor
1. Background
Cell therapy is a relatively new approach for treatment
of diseases by introducing new cells into a tissue. Mes-
enchymal stem cells (MSC), in particular, are considered
as an agent for cell therapy. In order to succeed in cell
therapy, a reliable in vivo imaging method in localizing
transplanted cells makes systematic investigation of cell
therapy possible (1-4). Previous researches with immuno-
histological staining were not usable to trace the migra-
tion of transplanted cells in vivo. Instead, molecular imag-
ing including nuclear imaging, optical imaging, and mag-
netic resonance (MR) imaging (5-7) allows visualization of
targeted cells in living organisms. In particular, molecu-
lar imaging with nanoparticles makes non-invasive mon-
itoring of target cells without sacrifice of subjects and re-
peated evaluation possible (8-11). Labeling cells with super-
paramagnetic iron oxide (SPIO) nanoparticles or a param-
agnetic contrast agent gadolinium (12) or manganese (4, 13,
14) provides the possibility of detecting single cells or clus-
ters of labeled cells within target tissues after either direct
implantation or intravenous injection (15-17).
Prostate cancer is the second most frequent cancer in
men in USA and it has the most rapidly increasing inci-
dence in Korea. Prostate specific antigen (PSA) for screen-
ing of prostate cancer and trans-rectal ultrasound (TRUS)-
guided biopsy allow the diagnosis of prostate cancer at
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an early stage (4). Regardless, radical prostatectomy (RP)
is a very common method in the treatment of prostate
cancer (18). The major complication of RP is the erectile
dysfunction (ED) (19), which is caused by loss of corporal
smooth muscle cells and subsequent fibrosis of the corpus
cavernosum by either direct damage or neuropraxia of the
cavernous nerve, alone or with hemodynamic alterations.
Nerve sparing surgery has been proposed to spare the erec-
tile function (20). However, no satisfying results have been
shown (21). Conversely, it has been reported that stem cell
injection improves erectile function in the rat model with
erection dysfunction (22).
2. Objectives
In this study, the rat animal model with ED by bilat-
eral cavernosal nerve (CN) injury was established to eval-
uate the feasibility for imaging of MSC treatment. There-
fore, MSCs isolated from human bone marrow were la-
beled with ferumoxides and were injected into the corpus
cavernosum of rats. The serial in vivo tracking of labeled
MSCs was performed by magnetic resonance (MR) imag-
ing. The mRNA expression of transforming growth factor-
β1 (TGF-β1) in rats injected with MSCs was compared to
the control rats in order to evaluate the beneficial effect of
MSCs on ED.
3. Materials and Methods
3.1. Animals and Cell Preparation
Animal protocols were approved by the animal studies
committee at the medical research center of Yonsei Univer-
sity. Male Sprague-Dawley rats (SLC, Tokyo, Japan), weigh-
ing 140± 5 g, were housed under standard laboratory con-
ditions (temperature 24 ± 2°C; humidity 50 ± 10%, 12-h
day/night cycles). Prior to experiments, animals were al-
lowed to acclimatize to the facility for one week, and were
provided a standard chow diet and drinking water ab libi-
tum. Animals were five weeks old on the first day of the ex-
posure study.
Mesenchymal stem cells (MSCs) used in this study were
donated by the department of orthopedic surgery in Yon-
sei University (Soeul, Korea). The MSCs were isolated from
human bone marrow without hematological and bone
marrow abnormality and were expanded in Dulbecco’s
Modified Eagle Medium (DMEM, Gibco, Carlsbad, CA, USA)
+ 10% fetal bovine serum (FBS, Gibco, Carlsbad, CA, USA) +
penicillin-streptomycin (Invitrogen, Carlsbad, CA, USA) in
a 37°C, 5% CO2 incubator.
3.2. Labeling MSCs with SPIO
In order to label MSCs, we employed ferumoxides
(Feridex IV, Bayer-Schering Pharma, Wayne, NJ, USA) as su-
perparamagnetic iron oxide (SPIO) nanoparticles for intra-
cellular magnetic labeling of stem cells to monitor cell traf-
ficking by MR imaging, and protamine sulfate (American
Pharmaceuticals Partner, Schaumburg, IL, USA) as a trans-
fection agent (23, 24). Briefly, ferumoxides (50 µg/mL) and
protamine sulfate (9 µg/mL) were added to the standard
culture medium and mixed for 10 minutes with intermit-
tent hand shakings, after which cells were incubated an-
other 2 hours. The equal volume of the culture medium
was then added to the cells, and cells were incubated in
37°C. After overnight incubation, the cells were washed
twice with heparin containing phosphate buffered saline,
collected, and counted for injection.
The efficiency of intracellular labeling of MSCs with
SPIO was determined with Prussian blue staining. The la-
beled 1× 106 cells were fixed with 95% alcohol and stained
with 10% potassium ferrocyanide (Perl’s reagent for Prus-
sian blue staining) and 3.7% hydrochloric acid for 20 min-
utes, after which the cells were counterstained with nu-
clear fast red. Cells containing intra-cytoplasmic blue in-
clusions were considered as Prussian blue positive. The
number of Prussian blue-stained and unstained cells were
counted using hemocytometer (× 100) under an inverted
microscope and labeling efficiency was determined by per-
centage of Prussian blue-stained positive cells over total
cells.
3.3. Cavernosal Nerve Injury andMSC Injection
Thirty-six (five weeks old, 12 per group) rats were di-
vided into 4 week, 8 week, and 16 week groups. Each group
was further divided into two subgroups, control and stem
cell groups (6 per subgroup). After anesthesia with an in-
traperitoneal injection of ketamine and xylazine, skin in-
cision was made. After transection of bilateral cavernosal
nerves, 1 × 106 MSCs in 0.02 mL media or 0.02 mL of cell-
free media were injected into the corpus cavernosum of
rats in stem cell groups or in control groups, respectively.
After the injection, the penile base was strangulated for 30
seconds and then released.
3.4. In vivo MR imaging
MRI was obtained with a 1.5 T clinical MRI scanner with
a micro-47 surface coil (InteraAchieva, Philips Medical Sys-
tems, Best, Netherlands). For in vivo penile MRI, the rats
were anesthetized with an intraperitoneal injection of ke-
tamine and xylazine and ferumoxides-labeled MSCs were
visualized by gradient echo sequence with the following
parameters: T1-turbo field echo sequence, shortest repeti-
tion time (TR) and echo time (TE), flip angle = 15°, matrix
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= 256 × 256, number of averages = 6, field of view = 80
mm. Gradient echo MR imaging was very sensitive to de-
tect the SPIO particles, which were detected as dark signal-
intensity. If there was a spot with dark signal-intensity on
injection site, we regarded that there were the SPIO-labeled
MSCs.
3.5. Fibrosis Analysis with Reverse Transcriptase Polymerase
Chain Reaction (RT-PCR)
For the fibrosis analysis, the rats were sacrificed at 4,
8, and 16 weeks of injection after MR imaging, and the pe-
nile tissues were collected. The expression of endogenous
transforming growth factor (TGF)-β1 mRNA in the penis
was evaluated by reverse transcriptase polymerase chain
reaction (RT-PCR). Total RNA was isolated using TRIzol (In-
vitrogen, NY, USA) and then processed for the first-strand
complementary DNA (cDNA) synthesis using reverse tran-
scriptase with oligo (dT) primers (Invitrogen, NY, USA). The
cDNA products were then amplified by PCR using T100TM
Thermal Cycler (bio-Rad, Hercules, CA). Primer sequences
were as follows; TGF-β1 forward 5’-GAT GAG ATC GAG TAC
ATC TT-3’, reverse 5’-CAC CGC CTC GGC TTG TCA CAT-3’; β-
actin forward 5’-TCT ACA ATG AGC TGC GTG TG -3’, reverse
5’-AAT GTC ACG CAC GAT TTC CC- 3’. The amplified PCR prod-
ucts were identified by electrophoresis using 1% agarose
gels containing ethidium bromide and then visualized un-
der UV light. The relative amount of TGF-β1 mRNA was cal-
culated as its ratio to β-actin from the same template. The
data are expressed as mean± standard deviation (SD). Two
group comparisons at the same period were evaluated by
a one-way analysis of variance (ANOVA). Differences were
considered statistically significant at P < 0.05. In addition,
a two-way ANOVA analysis was performed between time
and treatment. The statistical analysis was performed us-
ing IBM SPSS Statistics for Windows, Version 23.0. (Armonk,
NY: IBM Corp.).
3.6. Histological Analysis
The penile tissues were retrieved and fixed in 4%
paraformaldehyde. The specimens at the injection sites
were cut at a thickness of 4 µm in the short-axis plane and
stained with hematoxylin and eosin (H&E). Prussian blue
staining was also performed to detect ferumoxides-labeled
MSCs. The histological evaluation was performed under an
inverted microscope.
4. Results
4.1. Intracellular Labeling of MSCs with SPIO
MSCs isolated from human bone marrow were labeled
with ferumoxides as superparamagnetic iron oxide (SPIO)
nanoparticles for intracellular magnetic labeling to mon-
itor cell trafficking by MR imaging. The labeling efficacy
was examined under a microscope after Prussian complex
staining, which is a common stain to detect the presence
of iron. As shown in Figure 1, the most MSCs were labelled
with SPIO. The blue inclusions were easily detected at the
intra-cytoplasmic areas, whereas extracellular blue inclu-
sions were rarely examined.
Figure 1. Prussian blue-stained Feridex-labeled mesenchymal stem cells. Mesenchy-
mal stem cells were labeled with superparamagnetic iron oxide (SPIO) nanoparticles
for intracellular magnetic labeling and the efficacy of the labeling was examined un-
der a microscope after Prussian blue staining (× 1000).
4.2. In vivo MR Tracking of MSCs
SPIO labeled MSCs were then injected into the corpus
cavernosum of rats after radical prostatectomy. During the
experiments, one rat of MSC-injected group died in four
weeks, and the other one died in 8 weeks. The rest of the
34 rats was examined with MRI for in vivo tracking of MSCs
(Figure 2). After 4 weeks of injection into the corpus cav-
ernosum of the rats, the presence of SPIO-labeled MSCs
appeared as a hypointensity at the injection site demon-
strated by T1-weighted gradient-echo MR imaging (Figure
2A). Follow-up serial MR imaging revealed the decreased
sizes of hypointensity. After 12 weeks, most hypointensi-
ties were difficult to define (Figure 2C). However, the hy-
pointensity was not observed at the injection site in the
control group injected with cell-free media (Figure 2E).
4.3. Histological Analysis
In order to confirm the presence of SPIO-labeled MSCs
at the injection sites, the tissues collected from rats at 8
weeks of injection were stained with Prussian blue and
examined under a microscope. The intense intracellular
blue staining was observed with Prussian blue staining,
indicating intracellular iron-labeled cells, with iron exclu-
sions from the nucleus. The area of blue staining was cor-
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Figure 2. In vivo magnetic resonance (MR) imaging with superparamagnetic iron oxide (SPIO)-labeled mesenchymal stem cells after transection of bilateral cavernosal nerves.
A - E, Short axis T1-weighted gradient-echo MR imaging of rats showed the distinct hypointensity (indicated by arrows) at the penis 4 weeks (A) after injection. The size of
hypointensity became smaller gradually in rats after 8 (B), 12 (C), and 16 (D) weeks of injection. Conversely, no signal change was detected in a media-injected control rat (E).
responding to the hypointensity examined by MR imaging
(Figure 3).
4.4. RT-PCR Analysis for the mRNA Expression of TGF-β1
The expression of TGF-β1 was investigated from
the penile tissues of rats by semi-quantitative reverse
transcription-polymerase chain reaction (RT-PCR). The
band intensity was expressed as the ratio of TGF-β1 to
β-actin (Table 1). As shown in Figure 4, rats injected with
cell-free media after RP showed a significant increase of
TGF-β1 mRNA expression compared to untreated control
rats. Furthermore, the penile tissues from rats treated with
the stem cells for 4 weeks after RP showed a significant
decrease of TGF-β1 compared to rats in cell-free media in-
jected control groups. However, the expressions of TGF-β1
in rats treated with the stem cells for 8 or 16 weeks were not
significantly different from rats in media-injected control
groups (Figure 4A and 4B).
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Figure 3. Histological analysis of superparamagnetic iron oxide (SPIO)-labeled mes-
enchymal stem cells with Prussian blue staining. Rats at 8 weeks after injection of
SPIO-labeled mesenchymal stem cells into the corpus cavernosum were sacrificed
and the tissue was stained with Prussia blue staining. Hypointensities detected by
MR imaging were visible as blue stained area (indicated by arrows) by histologi-
cal examination with Prussian blue staining, indicating the presence of the intra-
cytoplasmic SPIO particles in the hypointensity.
Table 1. RT-PCR Analysis of TGF-β1 mRNA Expressiona
4 w 8 w 16 w
Control groups
0.617 0.432 0.512
0.614 0.456 0.39
0.566 0.352 0.408
0.591 0.347 0.359
0.535 0.309 0.316
0.55 0.366 0.266
Ave.± Std. Dev. 0.579± 0.0339 0.377± 0.0557 0.375± 0.0845
MSC injected
groups
0.556 0.487 0.636
0.521 0.539 0.522
0.471 0.487 0.575
0.542 0.373 0.504
0.397 0.334 0.329
0.484 0.35 0.275
Ave.± Std. Dev. 0.495± 0.0582 0.428± 0.0863 0.474± 0.0142
Abbreviations: MSC, mesenchymal stem cell; RT-PCR, reverse transcription-
polymerase chain reaction; TGF-β1, transforming growth factor-β1; W, week.
aAll data indicated the ratio of TGF- β1 and β-actin (TGF- β1 / β-actin) and Ave.
and Std. Dev. indicated the average value and standard deviation, respectively.
5. Discussion
Cell therapy is the process of introducing new cells
into a tissue for the treatment of a disease, and various
cell types are used in experimental models. In particu-
lar, MSCs are considered as an agent for cell therapy due
to their plasticity, established isolation procedures and ca-
pacity for ex vivo expansion (25). In order to achieve suc-
cess in cell therapy, noninvasive in vivo imaging methods
are required for monitoring the temporal-spatial migra-
tion of transplanted cells into a targeted organ. Much re-
search has been performed to find good techniques to de-
termine the localization of therapeutic cells transplanted
into the organs. Clinical nuclear medicine approaches ex-
hibited relatively short monitoring period of 2 - 3 days fol-
lowing the transplantation and possible damage to DNA
(26). In addition, optical and bioluminescent imaging ap-
proaches were limited in preclinical experiments due to
the introduction of toxic agents such as Qdots (27). Con-
versely, MR imaging with SPIO nanoparticles has several ad-
vantages such as high spatial resolution, long-term moni-
toring, and no-toxicity due to the biodegradable and me-
tabolizable nanoparticles (28). Therefore, in this study, the
MR imaging was employed to track the labeling MSCs with
ferumoxides, FDA-approved labeling agent for long-term
monitoring of transplanted cell-therapy into the clinic (29-
32).
ED limits the quality of life of man and his partner. ED
is known to be caused by the damage of penile cavernous
smooth muscle cells and sinus endothelial cells by var-
ious metabolic conditions or mechanical manipulations
(33, 34). In addition, RP, a dominant therapy for clinically
localized prostate cancer, is one of the main causes of ED
due to the injury of CN (35, 36). It is reported that many
patients following RP lost erectile ability coupled with a
gradual reduction in the size of the penis, increased apop-
tosis in penile tissues of rats after denervation, and de-
creased penile size. Several in vitro and in vivo studies re-
ported the possible treatment of ED such as oral phospho-
diesterase type 5 (PDE5) inhibitors and mesenchymal stem
cell-based cell and gene therapies. Unfortunately, PDE5 in-
hibitors are not effective for the patients with diabetes,
non-nerve sparing radical prostatectomy, and high disease
severity (37, 38). It was recently reported that transplanted
human MSCs have the potential to differentiate toward si-
nus endothelial cells or penile cavernous smooth muscle
cells, which are critical to maintain and regulate ED (39,
40). In this study, MSCs was injected into the corpus caver-
nosum of a rat with RP without nerve sparing and a clinical
MR scanner was applied to identify transplanted MSCs la-
beled with SPIO particles in in vivo rat models after radical
prostatectomy. Intracavernosal MSCs injection sites in the
rat penis appeared as hypointensity on in vivo MR imag-
ing. The SPIO nanoparticles shorten the T1, T2 and T2* re-
laxation times of water or tissue and have a high T2 relax-
ivity/T1 relaxivity ratio and significant capacity to reduce
MRI signal, which can be emphasized by using spin echo
sequences with longer echo time and by using gradient
echo sequences (41). Therefore, intracellular SPIO of trans-
planted cells could be readily detected as a hypointensity
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Figure 4. Reverse transcription-polymerase chain reaction (RT-PCR) analysis of transforming growth factor-β1 (TGF-β1) mRNA expression. A, Penile tissues from rats treated
with the stem cells for 4, 8, or 16 weeks were collected and the expression of TGF-β1 was analyzed by RT-PCR. (I; stem cell injected groups and C; control groups). B, Graphs
showing changes in the ratio of TGF-β1/ β-actin in the tissues. All data represent means± standard error from six rats from each group as a function of time. * , P < 0.01,
different from the control group in one-way ANOVA analysis. A two-way ANOVA between time and treatment indicated P < 0.05.
(dark lesion) by MR imaging. On the other hand, the hy-
pointensity showed the decrease in size along the serial
MR images. They were hardly detected after 12 weeks due
to death, migration, and differentiation of MSCs into the
smooth muscles and endothelial cells (42). However, the
exact mechanisms of disappearance of a hypointensity re-
quire further investigation.
TGF-β1 is one of the cytokines with a chemotactic role
in inflammatory cells and fibroblasts (43). It can modu-
late extracellular matrix by increasing the synthesis of its
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components and inhibiting the expression of hydrolytic
proteinases (44). Hypoxia can induce TGF-β1, which in-
creases collagen synthesis in human corpus cavernosal
smooth muscle cells in culture (45). Conversely, hypoxia
inhibits the production of prostaglandin E1 (PGE1), which
suppresses collagen synthesis and fibrosis induced by TGF-
β1 in human corpus cavernosal smooth muscle (46). A
high protein and mRNA expression of TGF-β1 in neurotomy
group suggests that ischemia and hypoxia may have oc-
curred in the penile tissues of rats after denervation (46). It
was also reported that the levels of TGF-β1 in plasma were
significantly increased in patients with ED, especially those
with a vasculogenic cause. It implicated that the increase
in TGF-β1 induces cavernosal fibrosis and ED after RD (47).
Therefore, increased expression of TGF-β1 in penile tissue
may be one of the important factors for the ED caused by
bilateral CN ablation. In the present study, we ablated both
CNs in a rat model, which mimics patients after RP with
no nerve sparing. The neurotomized rats in the 4-weeks
group showed the significant increase of mRNA expression
of TGF-β1 compared to the normal rats. These results are in
agreement with the previous report saying that the expres-
sion of TGF-β1 in neurotomized group was much higher
than in the sham-operated group both at the mRNA and
protein level (48). Furthermore, treatment of MSCs in neu-
rotomized rats exhibited a significant decrease of TGF-β1
compared to the rats in the neurotomized group and im-
plied reduction of hypoxia or ischemia induced by neuro-
tomy. These results suggested the potential beneficial ef-
fects of MSC injection to treat ED after radical prostatec-
tomy.
In summary, clinical MR imaging was applied to iden-
tify transplanted MSCs labeled with SPIO particle in in vivo
rat model after RP. The results demonstrated that MSCs la-
beled with SPIO could be tracked in vivo in the rat genitalia
of RP model up to 12 weeks. In addition, rats injected with
MSCs showed significantly lower levels of TGF-β1 compared
to the control rats, suggesting MSCs’ beneficial effects on
ED induced by RP. In conclusion, these results suggest that
MR imaging might be a viable tool for tracking and thera-
peutic monitoring in the future clinical study of stem cell
therapy in ED.
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